Propanc Biopharma reports pilot study shows anti-tumor efficacy for PRP proenzyme formulation in pancreatic, ovarian cancer

Bitget2026/10/14 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Propanc Biopharma reported results already presented in a newly published peer-reviewed pilot study in Scientific Reports on its PRP proenzyme therapy.
Preclinical tests showed PRP slowed tumor growth and reduced spread-related behavior in pancreatic and ovarian cancer models, with tolerable safety.
Separate UK Specials use in advanced cancers indicated longer-than-expected survival for a subset of patients, with no severe treatment-related events reported.
The data support continued development of PRP as a long-term, non-cytotoxic approach aimed at reducing recurrence and metastasis in solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140830PRIMZONEFULLFEED9845364) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Propanc Biopharma reports pilot study shows anti-tumor efficacy for PRP proenzyme formulation in pancreatic, ovarian cancer

You may also like

Crypto prices